- Glucagon-like Peptide-1 Analogue and Dipeptidyl Peptidase-IV Inhibitors
-
Oh S
- KMID: 2391898
- J Korean Endocr Soc.
- 2006 Dec;21(6):437-447.
No abstract available. -
- CITED
-
- Close
- SHARE
-
- Close
- Letter: Expression of Glucagon-Like Peptide-1 Receptor in Papillary Thyroid Carcinoma and Its Clinicopathologic Significance (Endocrinol Metab 2014;29:536-44, Min Jung Jung et al.)
-
Park D, Lee EK
- KMID: 2282016
- Endocrinol Metab.
- 2015 Jun;30(2):231-232.
- doi: 10.3803/EnM.2015.30.2.231
No abstract available. -
- CITED
-
- Close
- SHARE
-
- Close
- Pancreatic alpha-Cell Dysfunction in Type 2 Diabetes: Old Kids on the Block
-
Moon JS, Won KC
- KMID: 2280650
- Diabetes Metab J.
- 2015 Feb;39(1):1-9.
- doi: 10.4093/dmj.2015.39.1.1
Type 2 diabetes (T2D) has been known as 'bi-hormonal disorder' since decades ago, the role of glucagon from alpha-cell has languished whereas beta-cell taking center stage. Recently, numerous findings indicate... -
- CITED
-
- Close
- SHARE
-
- Close
- New Treatment for Type 2 Oiabetes: GLP-1 Analogue
-
Oh SJ
- KMID: 2294555
- J Korean Acad Fam Med.
- 2006 Nov;27(11):863-872.
No abstract available. -
- CITED
-
- Close
- SHARE
-
- Close
- Effects of Sitagliptin on Insulin and Glucagon Levels in Type 2 Diabetes Mellitus
-
Kim JH
- KMID: 2174025
- Diabetes Metab J.
- 2015 Aug;39(4):304-306.
- doi: 10.4093/dmj.2015.39.4.304
No abstract available. -
- CITED
-
- Close
- SHARE
-
- Close
- New Potential Targets of Glucagon-Like Peptide 1 Receptor Agonists in Pancreatic β-Cells and Hepatocytes
-
Lee WY
- KMID: 2413278
- Endocrinol Metab.
- 2017 Mar;32(1):1-5.
- doi: 10.3803/EnM.2017.32.1.1
It is well known that both insulin resistance and decreased insulin secretory capacity are important factors in the pathogenesis of type 2 diabetes mellitus (T2DM). In addition to genetic factors,... -
- CITED
-
- Close
- SHARE
-
- Close
- Response: Expression of Glucagon-Like Peptide-1 Receptor in Papillary Thyroid Carcinoma and Its Clinicopathologic Significance (Endocrinol Metab 2014;29:536-44, Min Jung Jung et al.)
-
Jung MJ, Kwon SK
- KMID: 2282017
- Endocrinol Metab.
- 2015 Jun;30(2):233-234.
- doi: 10.3803/EnM.2015.30.2.233
No abstract available. -
- CITED
-
- Close
- SHARE
-
- Close
- Glucagon-like peptide-1 and glucagon-like peptide-1 receptor agonists in the treatment of type 2 diabetes
-
Lee S, Lee DY
- KMID: 2409795
- Ann Pediatr Endocrinol Metab.
- 2017 Mar;22(1):15-26.
- doi: 10.6065/apem.2017.22.1.15
The prevalence of type 2 diabetes (T2D) is increasing worldwide. Patients with T2D suffer from various diabetes-related complications. Since there are many patients with T2D that cannot be controlled by... -
- CITED
-
- Close
- SHARE
-
- Close
- Therapeutic Potential of the Glucagon-like Peptide-1
-
Ko KS, Oh SJ, Kim TW
- KMID: 2063406
- J Korean Diabetes Assoc.
- 2004 Apr;28(2):51-62.
No abstract available. -
- CITED
-
- Close
- SHARE
-
- Close
- Clinical Efficacy of Glucagon Like Peptide-1 (GLP-1) Analogues
-
Chun HJ, Kwon HS
- KMID: 2173920
- J Korean Diabetes.
- 2013 Sep;14(3):125-127.
- doi: 10.4093/jkd.2013.14.3.125
Recently, incretin hormone-based therapies, including glucagon-like peptide-1 (GLP-1) analogues and dipeptidyl peptidase-4 (DPP-4) inhibitors, have become the main therapeutic tools in the hyperglycemia management in patients with type 2 diabetes... -
- CITED
-
- Close
- SHARE
-
- Close
- Extrapancreatic Effect of Glucagon like Peptide-1
-
Jeong IK
- KMID: 2268972
- Korean J Med.
- 2015 Oct;89(4):404-412.
- doi: 10.3904/kjm.2015.89.4.404
Glucagon like peptide-1 (GLP-1) is an intestinal L cell derived incretin hormone which stimulates insulin secretion of beta cell and inhibits glucagon secretion of alpha cell of pancreatic islets. GLP-1... -
- CITED
-
- Close
- SHARE
-
- Close
- The Effects of Hypoglycemic Agents on Non-alcoholic Fatty Liver Disease: Focused on Sodium-Glucose Cotransporter 2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists
-
Jung CH, Mok JO
- KMID: 2452623
- J Obes Metab Syndr.
- 2019 Mar;28(1):18-29.
- doi: 10.7570/jomes.2019.28.1.18
The only known, effective intervention for non-alcoholic fatty liver disease (NAFLD) is weight loss, and there is no approved pharmacotherapy. Recently, new hypoglycemic agents, such as sodium-glucose cotransporter 2 (SGLT2)... -
- CITED
-
- Close
- SHARE
-
- Close
- Food Intake and Gut Hormones
-
Cho YH, Lee SY
- KMID: 2271026
- Korean J Obes.
- 2013 Dec;22(4):197-204.
Peptide hormones, which regulate appetite, energy expenditure and glucose homeostasis, are released from the gastrointestinal tract in response to nutrients and they communicate information to the brain regarding the current... -
- CITED
-
- Close
- SHARE
-
- Close
- Higher glucagon-to-insulin ratio is associated with elevated glycated hemoglobin levels in type 2 diabetes patients
-
Lee M, Kim M, Park JS, Lee S, You J, Ahn CW, Kim KR, Kang S
- KMID: 2457030
- Korean J Intern Med.
- 2019 Sep;34(5):1068-1077.
- doi: 10.3904/kjim.2016.233
BACKGROUND/AIMS: The importance of α-cell dysfunction in the pathogenesis of type 2 diabetes has re-emerged recently. However, data on whether relative glucagon excess is present in clinical settings are scarce.... -
- CITED
-
- Close
- SHARE
-
- Close
- Clinical Application of Glucagon-Like Peptide-1 Receptor Agonists
-
Min SH, Cho YM
- KMID: 2173851
- J Korean Diabetes.
- 2015 Dec;16(4):252-259.
- doi: 10.4093/jkd.2015.16.4.252
Glucagon-like peptide 1 (GLP-1) is an incretin hormone that is released from enteroendocrine L-cells upon nutrient absorption; it stimulates glucose-dependent insulin secretion from pancreatic betacells. GLP-1 has pleiotropic effects including... -
- CITED
-
- Close
- SHARE
-
- Close
- Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Type 2 Diabetes Mellitus: A Position Statement of the Korean Diabetes Association
-
Kim HJ
- KMID: 2408656
- J Korean Diabetes.
- 2018 Mar;19(1):35-40.
- doi: 10.4093/jkd.2018.19.1.35
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) were recommended as a monotherapy or combination therapy with oral hypoglycemic agents or basal insulin in the position statement of the Korean Diabetes Association 2017... -
- CITED
-
- Close
- SHARE
-
- Close
- Pleiotropic Effects of an Incretin Hormone
-
Oh S
- KMID: 2173919
- J Korean Diabetes.
- 2013 Sep;14(3):120-124.
- doi: 10.4093/jkd.2013.14.3.120
The incretin hormones glucagon like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) have recently received much attention for their roles in type 2 diabetes therapy. GLP-1 stimulated insulin secretion in... -
- CITED
-
- Close
- SHARE
-
- Close
- GLP-1 Receptor Agonist and Non-Alcoholic Fatty Liver Disease
-
Lee J, Hong SW, Rhee EJ, Lee WY
- KMID: 2174417
- Diabetes Metab J.
- 2012 Aug;36(4):262-267.
- doi: 10.4093/dmj.2012.36.4.262
Non-alcoholic fatty liver disease (NAFLD), one of the most common liver diseases, is caused by the disruption of hepatic lipid homeostasis. It is associated with insulin resistance as seen in... -
- CITED
-
- Close
- SHARE
-
- Close
- Glucagon-Like Peptide-1 (GLP-1) Agonist
-
Eom YS, Kim BJ
- KMID: 2269256
- Korean J Med.
- 2014 Jul;87(1):9-13.
The prevalence of diabetes is increasing worldwide. Glycemic control has been shown to prevent microvascular complications. Many oral hyperglycemic drugs and insulin are being used in the treatment of diabetes,... -
- CITED
-
- Close
- SHARE
-
- Close
- The Incretins and Pancreatic beta-Cells: Use of Glucagon-Like Peptide-1 and Glucose-Dependent Insulinotropic Polypeptide to Cure Type 2 Diabetes Mellitus
-
Kim MH, Lee MK
- KMID: 2298038
- Korean Diabetes J.
- 2010 Feb;34(1):2-9.
- doi: 10.4093/kdj.2010.34.1.2
Type 2 diabetes mellitus (T2DM) is increasing in prevalence worldwide. The complications associated with T2DM result in increased mortality and financial cost for those affected. T2DM has long been known... -
- CITED
-
- Close
- SHARE
-
- Close
